“Edison’s accessible and high-quality research gives us the opportunity to communicate an independent perspective of Tyman to a wide variety of potential stakeholders.”
Currency in USD
Last close As at 27/03/2023
USD0.96
▲ 0.02 (2.13%)
Market capitalisation
USD16m
Kazia Therapeutics’ lead asset paxalisib (a PI3K inhibitor that can cross the blood brain barrier (BBB), licensed from Genentech) is in a pivotal study for glioblastoma (GBM) and in early-stage studies in childhood brain cancers, DIPG and AT/RT. Phase I EVT801 is an inhibitor of VEGFR3.
GBM is the most common primary cancer of the brain with c 12,500–13,000 new cases reported in the United States per year. There are very limited treatment options for GBM and there is a very low survival rate. Paxalisib is currently being developed for use in the adjuvant setting after initial resection and radiation treatment. EVT801 will target the multibillion-dollar angiogenesis cancer market.
Managing Director - Head of Content, Healthcare
Iain Ross
Chairman
James Garner
CEO
John Friend
CMO
Karen Krumeich
CFO
Forecast net debt (US$m)
6
Forecast gearing ratio (%)
224
| % | 1M | 3M | 12M |
|---|---|---|---|
| Actual | 8.0 | 90.1 | (87.3) |
| Relative | 8.1 | 83.0 | (85.4) |
| 52 week high/low | US$8.4/US$0.5 |
Kazia is developing the anti-cancer compound paxalisib (GDC-0084) for glioblastoma (GBM). Paxalisib is a PI3K inhibitor, a well understood class with activity across a wide range of tumour types and multiple previously approved drugs. Paxalisib, unlike other drugs of this class, can cross the blood brain barrier (BBB), opening the potential to treat cancers of the brain. Paxalisib has not progressed to stage 2 of the Phase III GBM AGILE study, although the first stage (~150 patients) remains ongoing, with final data expected in H2 CY23. A Phase II DIPG study (paxalisib in combination with ONC201) is ongoing at 22 sites globally, with initial data anticipated in CY23. With a recent A$4.5m fund-raise through a two-stage private placement, the period-end net cash balance stood at A$4.4m, which should provide headroom into H2 CY23, based on current burn rates.
| Y/E Jun | Revenue (US$m) | EBITDA (US$m) | PBT (US$m) | EPS (fd) (c) | P/E (x) | P/CF (x) |
|---|---|---|---|---|---|---|
| 2021A | 10.7 | (3.1) | (3.1) | (25.09) | N/A | N/A |
| 2022A | 0.0 | (14.9) | (14.9) | (110.57) | N/A | N/A |
| 2023E | 0.0 | (19.0) | (19.0) | (111.41) | N/A | N/A |
| 2024E | 10.8 | (17.2) | (17.2) | (82.84) | N/A | N/A |
